Concepedia

Klaus Charissé

KC

Statistics

Publications

60

Citations

8.9K

H-Index

39

Active since

1998

Affiliations

Alnylam Pharmaceuticals (United States)(Current)

Vanderbilt University

Massachusetts Institute of Technology

Harvard–MIT Division of Health Sciences and Technology

Binghamton University

Klaus Charissé is an author at Alnylam Pharmaceuticals (United States) specializing in molecular biology, rna interference, and life sciences.

Publications per year

1998–2023

60

Publications

60

Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery

Hyukjin Lee, Abigail K. R. Lytton‐Jean, Yi Chen et al. · Nature Nanotechnology · 2012 · 1.2K citations · Full text

Pharmacy, Molecular Biology, Pharmaceutics +14

Multivalent <i>N</i>-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

Jayaprakash K. Nair, Jennifer L. S. Willoughby, Amy Chan et al. · Journal of the American Chemical Society · 2014 · 1.1K citations

Pharmacy, Pharmaceutics, Pharmacology +17

Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown

Anders Wittrup, Angela Ai, Xing Liu et al. · Nature Biotechnology · 2015 · 661 citations · Full text

Pharmacy, Molecular Biology, Molecular Pharmaceutics +12

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Maria Frank-Kamenetsky, Aldo Grefhorst, Norma N. Anderson et al. · Proceedings of the National Academy of Sciences · 2008 · 639 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics

Martin A. Maier, Muthusamy Jayaraman, Shigeo Matsuda et al. · Molecular Therapy · 2013 · 619 citations · Full text

Pharmacy, Biotechnology, Pharmaceutics +17

1–5 of 60